Earnings Releases·Oct 29, 2026, 8:16 AM ET

Rafael Holdings — Fiscal Year 2026 Earnings Summary

Reported a narrowed net loss of $9.2 million ($0.18/share) for the quarter and $29.6 million ($0.58/share) for the full year, down from $12.1 million ($0.28/share) and $30.5 million ($1.04/share) respectively in the prior year, driven by a $4.4 million settlement gain and reduced G&A expenses, though revenue declined to $244,000 (quarter) and $874,000 (full year).
Submitted an NDA for remibetadex to treat Niemann-Pick Disease Type C, supported by a Phase 3 study that missed its primary endpoint but showed a 71% slowing of disease progression in a prespecified subgroup, while also securing an exclusive MIT license for Alzheimer's disease and launching a Phase II trial for Promitil®.
Cash and cash equivalents decreased to $22.1 million from $52.8 million in the prior year, and the company explicitly states there is substantial doubt about its ability to continue as a going concern with a need for additional financing.
Full-year R&D expenses rose to $24.3 million due to the consolidation of Cyclo Therapeutics, while G&A expenses fell to $9.7 million from $13.8 million, primarily due to reductions in payroll and stock-based compensation.